India may try to find 'middle ground' for usage and export of J&J single-shot jab
A strategy needs to be put in place where India may take a share of the monthly production of J&J’s vaccine for domestic use, said a senior government official privy to developments on this front The Indian government may initiate a fresh round of talks with Johnson & Johnson to find a middle ground on domestic usage and export of its vaccines manufactured by Biological E in India, as per a News18 report. However, a strategy needs to be put in place where India may take a share of the monthly production of J&J’s vaccine for domestic use. Indemnity demands of Pfizer, Moderna on backburner India is set to make 8 million doses of the Johnson and Johnson vaccine available by October-end, prime minister Modi had announced during the Quad Summit last weekend. “We need to figure out if the company plans to export these batches or they have been tested for technical reasons,” the official said while adding that for domestic use the issue of indemnity — that J&J has been demanding — needs to be sorted first.
Can a new vaccine rollout change this beaten down pharma MNC's fortune in 2023?
Covid: Biological E, Bharat Biotech together holding 250 million vaccine doses
Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses
UK-India Relationship Has Emerged Stronger Than Ever After the Covid Turbulence
India’s ‘other’ COVID vaccines: Status of under-trial & approved but unused jabs
A year on, Quad initiative for 1 billion India-made vaccines runs into rough weather
Covid-19: J&J's Hyderabad-made Jabs Get CDL Nod, Over 1 Cr Doses Ready for Export
Discover Related
What is the protocol for defence exports? | Explained
Indian pharma companies escape Trump’s reciprocal tariffs, for now
Sun Pharma, Gland, Cipla, Dr Reddy's: Why pharma stocks are rising today
Shashi Tharoor praises vaccine diplomacy: India enhanced its soft power
Trump's 25% auto tariff: Which Indian companies will pay the price
A bad omen for public trust in vaccines
Exports rise 30 times, 'Made in Bihar' boots used by Russia: Defence report
Letters to The Editor — March 19, 2025
Gujarat leads national vaccination day with 95.95% SDG-3 score
RFK Jr.’s First Month: Touting French Fries And Casting Doubts On Vaccines
Govt floats EOI for doing major Research & Development in pharma medtech sector and drugs
Telangana got Rs.15,000 crore investments at BioAsia summit, says Sridhar Babu
India eyes global pharma dominance with a ₹5,000 crore revitalisation plan
Biological E. to make Bavarian Nordic’s Chikungunya vaccine
Advances in vaccine technology and the road ahead
Bitter pill for Indian pharma as Trump tariffs could hurt exports by $2.25 billion
Biovet Gets CDSCO Approval for Lumpy Skin Disease Vaccine
Govt to collate journey of U-WIN so far to overcome challenges
Union Budget 2025: StockGro’s Chahat Aggarwal expects a growing pharmaceutical industry
Child vaccine coverage falling short in India, Lancet study reveals why
History Today: How India administered its first Covid-19 vaccine on this day
Indian Immunologicals Ltd hosts pandemic preparedness conclave in Hyderabad
Krishna Ella, of Bharat Biotech, conferred INSA Fellowship
Indian medtech firms eye exports as established MNCs dominate local market
Medical devices maker Poly Medicure to focus on exports amid geopolitical shift
JWS Infra to spend Rs 30,000 crore by FY30 to expand cargo-handling capacity to 400 MTPA
Serum Institute to manufacture Mpox vaccine by Danish maker Bavarian Nordic